ARTICLES BY RONALD A. RADER
-
![Tree-growth-increase-iStock-924834270]( "Biosimilars Pipeline Shows Remarkable, Sustained Growth")
Biosimilars Pipeline Shows Remarkable, Sustained GrowthThe biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress.
-
![2019-iStock-892736210]( "Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019")
Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.
-
![biosimilar pipeline]( "Biosimilars Pipeline Analysis: Many Products, More Competition Coming")
Biosimilars Pipeline Analysis: Many Products, More Competition ComingOur discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.
Ronald A. Rader
Ronald A. Rader, senior director of technical research at BioPlan Associates, Inc., has 30+ years of experience as a biotechnology, pharmaceutical, and chemical information specialist/analyst. He was editor/publisher of the Antiviral Agents Bulletin, Federal Bio-Technology Transfer Directory, and BIOPHARMA: Biopharmaceutical Products in the U.S. Market.